Berger, Anne Katrin
Lücke, Stephan
Abel, Ulrich
Haag, Georg Martin
Grüllich, Carsten
Stange, Annika
Dietrich, Mareike
Apostolidis, Leonidas
Freitag, Angelika
Trierweiler, Claudia
von Gall, Carl
Ose, Jennifer
Giesel, Frederik
Weber, Tim Frederik
Lordick, Florian
Haberkorn, Uwe
Jäger, Dirk
Article History
Received: 8 February 2018
Revised: 21 May 2018
Accepted: 29 May 2018
First Online: 2 July 2018
Competing interests
: The authors declare no competing interests.
: The study was approved by the local Ethics Committee (Ethics Committee University of Heidelberg). The protocol was approved by the national regulatory authorities according to the requirements of §40ff. AMG (German Drug Law). All aspects of the study were done in accordance with the declaration of Helsinki and the guidelines for Good Clinical Practice of the International Conference on Harmonization.
: All data are available via the corresponding author and the NCT trial centre.
: This study is an investigator-initiated trial, funded by Merck Pharma GmbH. The contract between the financial sponsor and the University Hospital of Heidelberg leaves the full responsibility for the scientific work, the management of data, and for analysis and publication to the investigators.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).